T1	Participants 102 132	familial adenomatous polyposis
T2	Participants 237 287	patients with familial adenomatous polyposis (FAP)
T3	Participants 1044 1055	41 patients
T4	Participants 1186 1255	sulindac-treated patients who did not develop adenomas ("responders")
T5	Participants 1371 1432	patients on sulindac who developed adenomas ("nonresponders")
